ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MLYS vs ANIP // FREE CASH FLOW YIELD

Mineralys Therapeutics Inc. (NASDAQ) VS. ANI Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: MLYS 0 — ANIP 6
▲ FREE CASH FLOW YIELD LEADER: ANIP
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MLYS VS. ANIP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MLYS ANIP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -28.40% 16.00% -44.40 ANIP /roic <GO>
EV/EBITDA & P/E Valuation — 13.7x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -7.58% 10.20% -17.78 ANIP /fcf-yield <GO>
Operating Margin — 12.60% — TIE /operating-margins <GO>
Net Profit Margin — 8.80% — TIE /net-margins <GO>
Revenue Growth (YoY) — 43.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.07% -0.07 ANIP /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 2.36 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 8/9 -5.00 ANIP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.9 47.3 -10.40 ANIP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 18.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.61B $1.65B -$45.8M ANIP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MLYS REV ANIP REV MLYS GROSS % ANIP GROSS % MLYS FCF ANIP FCF
FY 2025 $477.7M $883.4M — — -$142.4M $171.4M
FY 2024 $538.7M $614.4M — — -$166.3M $47.8M
FY 2023 $237.0M $486.8M — — -$81.2M $119.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MLYS // BETA —
ANIP // BETA —